Hair loss and weight gain have not been reported in clinical trials as side effects of treatment with Vyvgart Hytrulo. Patients are advised to speak with their healthcare provider if they experience any unusual symptoms or side effects while on the medication.
FAQs
According to data from the ADAPT-SC trial, which supported the approval of Vyvgart Hytrulo for people with generalized myasthenia gravis, some patients may see results as early as one week after treatment initiation. However, because each person may respond differently to treatment, patients…
Efgartigimod alfa, a key component of Vyvgart Hytrulo, has been reported to have no or a negligible impact on a person’s ability to drive and use machines. Nevertheless, it’s recommended patients be careful before attempting to drive or use any machines until they know how Vyvgart Hytrulo affects them. Patients…
There are no available data on the use of Vyvgart Hytrulo during pregnancy in humans. In animal studies, administration of efgartigimod alfa and hyaluronidase — both components of Vyvgart Hytrulo — were generally not associated with adverse developmental effects during pregnancy or after birth. Yet, it’s recommended patients who are…
The U.S. Food and Drug Administration (FDA) approved Vyvgart Hytrulo in June 2023 to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor. With that decision, Vyvgart Hytrulo became the first therapy administered via an under-the-skin injection to gain approval in the U.S.
Neither hair loss nor weight gain have been reported in clinical trials as side effects of Rystiggo. It is recommended patients speak with their healthcare team if they experience any unanticipated side effects while on the medication.
In the MycarinG clinical trial that supported Rystiggo’s approval, patients with generalized myasthenia gravis (gMG) experienced improvements in measures of disease severity as early as eight days after starting treatment. However, each patient is unique and may respond differently to treatment. All are advised to talk with their healthcare team…
It is unclear whether Rystiggo can affect a person’s ability to drive and use machinery. Patients should be careful before attempting to drive or use any machinery until they know how the therapy affects them. Patients planning to start taking Rystiggo are advised to talk with their healthcare team to…
Rystiggo has not been rigorously studied in pregnant people, but animal data suggests it may cause fetal harm. Patients who are pregnant or planning to become pregnant should discuss this topic with their healthcare providers.
The U.S. Food and Drug Administration (FDA) approved Rystiggo in June 2023 as a treatment for adults with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor or muscle-specific kinase — the two most common types of disease-driving antibodies. The approval made Rystiggo the first therapy…
Recent Posts
- Regaining control over life when MG weighs me down
- New US patient registry to track MG using real-world data
- Standard treatments don’t always work for triple-seronegative MG
- Exercise, breathing training may help ease myasthenia gravis symptoms
- I learn asking for help means choosing not to do everything the hard way